Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €44.72 EUR
Change Today +0.78 / 1.78%
Volume 72.1K
As of 11:35 AM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

ipsen (IPN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/17/15 - €46.81
52 Week Low
04/11/14 - €28.24
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IPSEN (IPN)

Related News

No related news articles were found.

ipsen (IPN) Related Businessweek News

View More BusinessWeek News

ipsen (IPN) Details

Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

4,500 Employees
Last Reported Date: 03/3/15
Founded in 1929

ipsen (IPN) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: €1.4M
Deputy Chief Executive Officer and Interim Ex...
Total Annual Compensation: €1.1M
Compensation as of Fiscal Year 2013.

ipsen (IPN) Key Developments

Lexicon Pharmaceuticals, Inc. and Ipsen S.A. Expand Their Licensing and Commercialization Agreement for Telotristat Etiprate to Include Canada

Lexicon Pharmaceuticals, Inc. and Ipsen S.A. announced that they have entered into an agreement for Ipsen, upon regulatory approval, to commercialize telotristat etiprate in Canada, with a focus on the treatment of carcinoid syndrome. This agreement represents an expansion of the licensing agreement previously entered into by Ipsen and Lexicon in October 2014. Under the expanded alliance, Lexicon retains sole rights to commercialize telotristat etiprate in the United States and Japan. Under the financial terms of the agreement, Lexicon is eligible to receive up to $5 million in upfront and pre-commercialization milestones. Net sales in Canada will be aggregated with those in Europe and other territories licensed to Ipsen for purposes of the royalties and sales milestones to be paid to Lexicon under the agreement.

Ipsen S.A. Proposes Payment of Dividend for the Year 2014

The Board of Directors of Ipsen S.A., which met on 2 March 2015, has decided to propose at Ipsen’s annual shareholders’ meeting to be held on 27 May 2015 the payment of a dividend of €0.85 per share, up €0.05 year-on-year, representing a pay-out ratio of approximately 45% of consolidated net profit (attributable to the Group’s shareholders), compared to a pay-out ratio of approximately 44% for the 2013 financial year.

Ipsen S.A. Reports Audited Consolidated Earnings Results for the Year December 31, 2014

Ipsen S.A. reported audited consolidated earnings results for the year December 31, 2014. For the year, the company reported sales of EUR 1,274.8 million against EUR 1,224.8 million a year ago. Total revenues were EUR 1,332.4 million against EUR 1,281.8 million a year ago. Core operating profit was EUR 260.6 million against EUR 228.0 million a year ago. Operating profit was EUR 221.4 million against EUR 210.5 million a year ago. Consolidated net profit was EUR 154.0 million against EUR 153.1 million a year ago. Diluted core EPS was EUR 2.22 against EUR 1.84 a year ago. Profit from continuing operations came to 154.5 million, up 8.6% from 142.2 million at 31 December 2013. Core net profit amounted to EUR 182.6 million, sharply up compared to the EUR 153.7 million recorded at 31 December 2013. Consolidated net profit attributable to shareholders of the company was EUR 153.5 million against EUR 152.5 million a year ago. Net cash flow from operating activities was EUR 246.2 million against EUR 181.4 million a year ago. Net investments in financial and tangible and intangible assets were EUR 84.2 million against EUR 62.3 million a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPN:FP €44.72 EUR +0.78

IPN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €17.14 EUR +0.22
Meda AB kr137.80 SEK +2.10
Orion Oyj €26.68 EUR +0.42
Procter & Gamble Hygiene & Health Care Ltd 7,270 INR +60.80
Recordati SpA €17.60 EUR +0.92
View Industry Companies

Industry Analysis


Industry Average

Valuation IPN Industry Range
Price/Earnings 21.1x
Price/Sales 2.4x
Price/Book 3.0x
Price/Cash Flow 21.3x
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IPSEN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at